Arizona State Retirement System Sells 1,590 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Arizona State Retirement System decreased its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 34,216 shares of the biopharmaceutical company’s stock after selling 1,590 shares during the period. Arizona State Retirement System’s holdings in Dynavax Technologies were worth $437,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Aigen Investment Management LP raised its position in Dynavax Technologies by 41.3% in the fourth quarter. Aigen Investment Management LP now owns 28,943 shares of the biopharmaceutical company’s stock worth $370,000 after acquiring an additional 8,456 shares during the period. Charles Schwab Investment Management Inc. raised its position in Dynavax Technologies by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company’s stock worth $14,750,000 after acquiring an additional 32,347 shares during the period. Smartleaf Asset Management LLC raised its position in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,034 shares during the period. Bank of New York Mellon Corp raised its position in Dynavax Technologies by 4.4% in the fourth quarter. Bank of New York Mellon Corp now owns 931,328 shares of the biopharmaceutical company’s stock worth $11,893,000 after acquiring an additional 39,513 shares during the period. Finally, Handelsbanken Fonder AB raised its position in Dynavax Technologies by 9.5% in the fourth quarter. Handelsbanken Fonder AB now owns 49,700 shares of the biopharmaceutical company’s stock worth $635,000 after acquiring an additional 4,300 shares during the period. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $13.87 on Friday. The company has a 50 day moving average of $13.11 and a 200 day moving average of $12.30. The stock has a market cap of $1.72 billion, a P/E ratio of 77.06 and a beta of 1.23. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $14.63. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, sell-side analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on DVAX shares. HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.